Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
roche
3
×
san francisco blog main
biotech
cancer
deals
detroit blog main
detroit top stories
fda
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
accelerator
advaxis
aimmune therapeutics
airbnb
alder biopharmaceuticals
alexander hardy
amazon web services (aws)
andrew oxtoby
artificial intelligence (a.i.)
athelas
atomwise
babies
benchling
biotechnology
What
big
3
×
medicine
acquire
admits
ago
agreed
billion
bio
biotechs
bosley's
bosley’s
bridge
broad
bucks
cas
ceo
classes
combinator
companies
confidence
crime
crispr
departure
didn’t
dug
editas
exit
foundation
gain
genentech
guiding
incubator
katrine
life
momentum
morning
moves
panels
pay
pays
Language
unset
Current search:
roche
×
big
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
